These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

218 related articles for article (PubMed ID: 21712426)

  • 1. Regulation of ingestive behaviors in the rat by GSK1521498, a novel micro-opioid receptor-selective inverse agonist.
    Ignar DM; Goetz AS; Noble KN; Carballo LH; Stroup AE; Fisher JC; Boucheron JA; Brainard TA; Larkin AL; Epperly AH; Shearer TW; Sorensen SD; Speake JD; Hommel JD
    J Pharmacol Exp Ther; 2011 Oct; 339(1):24-34. PubMed ID: 21712426
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Opioid receptor modulation of hedonic taste preference and food intake: a single-dose safety, pharmacokinetic, and pharmacodynamic investigation with GSK1521498, a novel μ-opioid receptor inverse agonist.
    Nathan PJ; O'Neill BV; Bush MA; Koch A; Tao WX; Maltby K; Napolitano A; Brooke AC; Skeggs AL; Herman CS; Larkin AL; Ignar DM; Richards DB; Williams PM; Bullmore ET
    J Clin Pharmacol; 2012 Apr; 52(4):464-74. PubMed ID: 21610207
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inhibition of opioid transmission at the μ-opioid receptor prevents both food seeking and binge-like eating.
    Giuliano C; Robbins TW; Nathan PJ; Bullmore ET; Everitt BJ
    Neuropsychopharmacology; 2012 Nov; 37(12):2643-52. PubMed ID: 22805601
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacological characterization of 2-methyl-N-((2'-(pyrrolidin-1-ylsulfonyl)biphenyl-4-yl)methyl)propan-1-amine (PF-04455242), a high-affinity antagonist selective for κ-opioid receptors.
    Grimwood S; Lu Y; Schmidt AW; Vanase-Frawley MA; Sawant-Basak A; Miller E; McLean S; Freeman J; Wong S; McLaughlin JP; Verhoest PR
    J Pharmacol Exp Ther; 2011 Nov; 339(2):555-66. PubMed ID: 21821697
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Multiple-dose safety, pharmacokinetics, and pharmacodynamics of the μ-opioid receptor inverse agonist GSK1521498.
    Nathan PJ; Bush MA; Tao WX; Koch A; Davies KM; Maltby K; O'Neill BV; Napolitano A; Skeggs AL; Brooke AC; Richards DB; Williams PM; Bullmore ET
    J Clin Pharmacol; 2012 Oct; 52(10):1456-67. PubMed ID: 22162534
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antiobesity efficacy of a novel cannabinoid-1 receptor inverse agonist, N-[(1S,2S)-3-(4-chlorophenyl)-2-(3-cyanophenyl)-1-methylpropyl]-2-methyl-2-[[5-(trifluoromethyl)pyridin-2-yl]oxy]propanamide (MK-0364), in rodents.
    Fong TM; Guan XM; Marsh DJ; Shen CP; Stribling DS; Rosko KM; Lao J; Yu H; Feng Y; Xiao JC; Van der Ploeg LH; Goulet MT; Hagmann WK; Lin LS; Lanza TJ; Jewell JP; Liu P; Shah SK; Qi H; Tong X; Wang J; Xu SS; Francis B; Strack AM; MacIntyre DE; Shearman LP
    J Pharmacol Exp Ther; 2007 Jun; 321(3):1013-22. PubMed ID: 17327489
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Characterization of a novel and selective cannabinoid CB1 receptor inverse agonist, Imidazole 24b, in rodents.
    Shearman LP; Stribling DS; Camacho RE; Rosko KM; Wang J; Tong S; Feng Y; Marsh DJ; Yu H; Guan X; Spann SK; Macneil DJ; Fong TM; Metzger JM; Goulet MT; Hagmann WK; Plummer CW; Finke PE; Mills SG; Shah SK; Truong Q; Van der Ploeg LH; Macintyre DE; Strack AM
    Eur J Pharmacol; 2008 Jan; 579(1-3):215-24. PubMed ID: 18021763
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A selective cannabinoid-1 receptor antagonist, PF-95453, reduces body weight and body fat to a greater extent than pair-fed controls in obese monkeys.
    Wagner JD; Zhang L; Kavanagh K; Ward GM; Chin JE; Hadcock JR; Auerbach BJ; Harwood HJ
    J Pharmacol Exp Ther; 2010 Oct; 335(1):103-13. PubMed ID: 20605903
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The opioid receptor pharmacology of GSK1521498 compared to other ligands with differential effects on compulsive reward-related behaviours.
    Kelly E; Mundell SJ; Sava A; Roth AL; Felici A; Maltby K; Nathan PJ; Bullmore ET; Henderson G
    Psychopharmacology (Berl); 2015 Jan; 232(1):305-14. PubMed ID: 24973897
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Opposing effects of intra-nucleus accumbens mu and kappa opioid agonists on sensory specific satiety.
    Woolley JD; Lee BS; Kim B; Fields HL
    Neuroscience; 2007 Jun; 146(4):1445-52. PubMed ID: 17445988
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of the mu-opioid receptor antagonist GSK1521498 on hedonic and consummatory eating behaviour: a proof of mechanism study in binge-eating obese subjects.
    Ziauddeen H; Chamberlain SR; Nathan PJ; Koch A; Maltby K; Bush M; Tao WX; Napolitano A; Skeggs AL; Brooke AC; Cheke L; Clayton NS; Sadaf Farooqi I; O'Rahilly S; Waterworth D; Song K; Hosking L; Richards DB; Fletcher PC; Bullmore ET
    Mol Psychiatry; 2013 Dec; 18(12):1287-93. PubMed ID: 23147384
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Investigation of the effects of opiate antagonists infused into the nucleus accumbens on feeding and sucrose drinking in rats.
    Kelley AE; Bless EP; Swanson CJ
    J Pharmacol Exp Ther; 1996 Sep; 278(3):1499-507. PubMed ID: 8819538
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Chronic prevention of mu-opioid receptor (MOR) G-protein coupling in the pontine parabrachial nucleus persistently decreases consumption of standard but not palatable food.
    Ward HG; Simansky KJ
    Psychopharmacology (Berl); 2006 Sep; 187(4):435-46. PubMed ID: 16847679
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Nucleus accumbens dopamine and mu-opioid receptors modulate the reinstatement of food-seeking behavior by food-associated cues.
    Guy EG; Choi E; Pratt WE
    Behav Brain Res; 2011 Jun; 219(2):265-72. PubMed ID: 21262268
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of [Dmt1]DALDA and DAMGO in binding and G protein activation at mu, delta, and kappa opioid receptors.
    Zhao GM; Qian X; Schiller PW; Szeto HH
    J Pharmacol Exp Ther; 2003 Dec; 307(3):947-54. PubMed ID: 14534366
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacological differentiation of opioid receptor antagonists by molecular and functional imaging of target occupancy and food reward-related brain activation in humans.
    Rabiner EA; Beaver J; Makwana A; Searle G; Long C; Nathan PJ; Newbould RD; Howard J; Miller SR; Bush MA; Hill S; Reiley R; Passchier J; Gunn RN; Matthews PM; Bullmore ET
    Mol Psychiatry; 2011 Aug; 16(8):826-35, 785. PubMed ID: 21502953
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Intake of saccharin, salt, and ethanol solutions is increased by infusion of a mu opioid agonist into the nucleus accumbens.
    Zhang M; Kelley AE
    Psychopharmacology (Berl); 2002 Feb; 159(4):415-23. PubMed ID: 11823894
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The novel mu-opioid antagonist, GSK1521498, reduces ethanol consumption in C57BL/6J mice.
    Ripley TL; Sanchez-Roige S; Bullmore ET; Mugnaini M; Maltby K; Miller SR; Wille DR; Nathan P; Stephens DN
    Psychopharmacology (Berl); 2015 Sep; 232(18):3431-41. PubMed ID: 26141191
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacological evaluation of LH-21, a newly discovered molecule that binds to cannabinoid CB1 receptor.
    Chen RZ; Frassetto A; Lao JZ; Huang RR; Xiao JC; Clements MJ; Walsh TF; Hale JJ; Wang J; Tong X; Fong TM
    Eur J Pharmacol; 2008 Apr; 584(2-3):338-42. PubMed ID: 18336811
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Characterization of a novel bivalent morphinan possessing kappa agonist and micro agonist/antagonist properties.
    Mathews JL; Peng X; Xiong W; Zhang A; Negus SS; Neumeyer JL; Bidlack JM
    J Pharmacol Exp Ther; 2005 Nov; 315(2):821-7. PubMed ID: 16076937
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.